Old Web
English
Sign In
Acemap
>
authorDetail
>
Anne Haberkorn
Anne Haberkorn
Novartis
KRAS
Cancer research
Trametinib
Cancer cell
Receptor tyrosine kinase
2
Papers
36
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Abstract A44: SHP2 inhibition overcomes RTK-mediated pathway reactivation in KRAS-mutant tumors treated with MEK inhibitors
2020
Molecular Cancer Research
Hengyu Lu
Chen Liu
Roberto Velazquez
Hongyun Wang
Lukas M. Dunkl
Malika Kazic-Legueux
Anne Haberkorn
Eric Billy
Eusebio Manchado
Saskia M. Brachmann
Susan E. Moody
Jeffrey A. Engelman
Peter S. Hammerman
Giordano Caponigro
Morvarid Mohseni
Huai-Xiang Hao
Show All
Source
Cite
Save
Citations (0)
SHP2 inhibition overcomes RTK-mediated pathway re-activation in KRAS mutant tumors treated with MEK inhibitors
2019
Molecular Cancer Therapeutics
Hengyu Lu
Chen Liu
Roberto Velazquez
Hongyun Wang
Lukas Manuel Dunkl
Malika Kazic-Legueux
Anne Haberkorn
Eric Billy
Eusebio Manchado
Saskia Brachmann
Susan E. Moody
Jeffrey A. Engelman
Peter S. Hammerman
Giordano Caponigro
Morvarid Mohseni
Huaixiang Hao
Show All
Source
Cite
Save
Citations (36)
1